[go: up one dir, main page]

TNSN08139A1 - Composes therapeutiques - Google Patents

Composes therapeutiques

Info

Publication number
TNSN08139A1
TNSN08139A1 TNP2008000139A TNSN08139A TNSN08139A1 TN SN08139 A1 TNSN08139 A1 TN SN08139A1 TN P2008000139 A TNP2008000139 A TN P2008000139A TN SN08139 A TNSN08139 A TN SN08139A TN SN08139 A1 TNSN08139 A1 TN SN08139A1
Authority
TN
Tunisia
Prior art keywords
therapeutic compounds
solvates
processes
formula
preparation
Prior art date
Application number
TNP2008000139A
Other languages
English (en)
Inventor
Brian Douglas Patterson
Sylvie Kim Sakata
Mitchell David Nambu
Leena Bharat Kumar Patel
John Howard Tatlock
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN08139A1 publication Critical patent/TNSN08139A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention propose des composés de formule (I), ou leurs sels ou produits de solvatation pharmaceutiquement acceptables, des procédés pour leur préparation, des méthodes pour leur utilisation, et des compositions pharmaceutiques les contenant.
TNP2008000139A 2005-09-23 2008-03-19 Composes therapeutiques TNSN08139A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US72015105P 2005-09-23 2005-09-23
US72311505P 2005-10-03 2005-10-03
US72546905P 2005-10-11 2005-10-11
US76225606P 2006-01-25 2006-01-25
US82166406P 2006-08-07 2006-08-07
PCT/IB2006/002639 WO2007034312A2 (fr) 2005-09-23 2006-09-11 Composes therapeutiques

Publications (1)

Publication Number Publication Date
TNSN08139A1 true TNSN08139A1 (fr) 2009-07-14

Family

ID=37889174

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000139A TNSN08139A1 (fr) 2005-09-23 2008-03-19 Composes therapeutiques

Country Status (28)

Country Link
US (1) US7868026B2 (fr)
EP (1) EP1937639B1 (fr)
JP (1) JP4336738B2 (fr)
KR (1) KR100975448B1 (fr)
CN (1) CN101287708B (fr)
AT (1) ATE459603T1 (fr)
AU (1) AU2006293605B2 (fr)
BR (1) BRPI0616156A2 (fr)
CA (1) CA2621805C (fr)
CY (1) CY1110010T1 (fr)
DE (1) DE602006012713D1 (fr)
DK (1) DK1937639T3 (fr)
EA (1) EA014329B1 (fr)
EC (1) ECSP088296A (fr)
ES (1) ES2340200T3 (fr)
GE (1) GEP20115230B (fr)
HR (1) HRP20100272T2 (fr)
IL (1) IL189666A (fr)
MA (1) MA29791B1 (fr)
MY (1) MY143391A (fr)
NO (1) NO20081844L (fr)
NZ (1) NZ566136A (fr)
PL (1) PL1937639T3 (fr)
PT (1) PT1937639E (fr)
RS (2) RS51349B (fr)
SI (1) SI1937639T1 (fr)
TN (1) TNSN08139A1 (fr)
WO (1) WO2007034312A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511812A (zh) * 2006-07-05 2009-08-19 辉瑞产品公司 作为细胞色素p450抑制剂的吡唑衍生物
WO2008088540A2 (fr) * 2006-12-26 2008-07-24 Amgen Inc. N-cyclohexyl benzamides et benzène acétamides utilisés comme inhibiteurs de 11-beta-hydroxysteroïdes déshydrogenases
EP2126574B1 (fr) 2007-03-08 2015-12-23 The Board of Trustees of the Leland Stanford Junior University Modulateurs de l'aldéhyde deshydrogènase-2 mitochondrial, et leurs procédés d'utilisation
WO2009043784A1 (fr) * 2007-10-04 2009-04-09 F. Hoffmann-La Roche Ag Dérivés de cyclopropyl aryl amides et leurs utilisations
EP2337563B1 (fr) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulateurs de l'activité de l'aldéhyde déshydrogénase et leurs procédés d'utilisation
CN102202669A (zh) 2008-10-28 2011-09-28 利兰·斯坦福青年大学托管委员会 醛脱氢酶调节剂及其使用方法
EA020460B1 (ru) 2009-01-12 2014-11-28 Пфайзер Лимитед Производные сульфонамида
MX2011011428A (es) * 2009-05-01 2011-11-29 Raqualia Pharma Inc Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
EP2590972B1 (fr) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides comme inhibiteurs des canaux sodiques voltage-dépendant
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
WO2014000178A1 (fr) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Dérivés de sulfamide et leurs méthodes d'utilisation permettant d'améliorer la pharmacocinétique d'un médicament
CN104540813A (zh) * 2012-06-27 2015-04-22 默沙东公司 磺酰胺衍生物以及使用它们用于改善药物的药物动力学的方法
WO2014160185A2 (fr) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Modulateurs de l'aldéhyde déshydrogénase-2 mitochondriale et leurs procédés d'utilisation
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
WO2014194519A1 (fr) 2013-06-07 2014-12-11 Merck Sharp & Dohme Corp. Dérivés imidazole et leurs procédés d'utilisation pour l'amélioration des propriétés pharmacocinétiques d'un médicament
WO2015070366A1 (fr) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Dérivés d'imidazole et de triazole liés à aryle et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
WO2015070367A1 (fr) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Dérivés d'imidazole et de triazole liés à la pipéridine ou la pipérazine et leurs procédés d'utilisation pour améliorer la pharmacocinétique d'un médicament
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
WO2016101118A1 (fr) * 2014-12-23 2016-06-30 Merck Sharp & Dohme Corp. Antagonistes des récepteurs d'orexine de type amidoéthylazole
KR20180043837A (ko) 2015-09-04 2018-04-30 에프. 호프만-라 로슈 아게 페녹시메틸 유도체
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
CN116903531A (zh) * 2023-07-21 2023-10-20 上海中医药大学 细胞色素p450酶3a4的抑制剂及其制备方法与应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169763B2 (en) 2002-02-22 2007-01-30 Oliver Yoa-Pu Hu Cytochrome P450 3A inhibitors and enhancers

Also Published As

Publication number Publication date
NZ566136A (en) 2010-04-30
EA014329B1 (ru) 2010-10-29
CA2621805A1 (fr) 2007-03-29
US7868026B2 (en) 2011-01-11
RS20080118A (sr) 2009-05-06
WO2007034312A3 (fr) 2007-08-23
AU2006293605B2 (en) 2011-05-19
EP1937639A2 (fr) 2008-07-02
CN101287708A (zh) 2008-10-15
JP2009508931A (ja) 2009-03-05
KR20080038431A (ko) 2008-05-06
IL189666A0 (en) 2008-08-07
MY143391A (en) 2011-05-13
ECSP088296A (es) 2008-06-30
SI1937639T1 (sl) 2010-07-30
CY1110010T1 (el) 2015-01-14
ES2340200T3 (es) 2010-05-31
EP1937639B1 (fr) 2010-03-03
DE602006012713D1 (de) 2010-04-15
IL189666A (en) 2011-12-29
HRP20100272T1 (en) 2010-06-30
JP4336738B2 (ja) 2009-09-30
EA200800542A1 (ru) 2008-08-29
GEP20115230B (en) 2011-06-10
DK1937639T3 (da) 2010-05-10
KR100975448B1 (ko) 2010-08-11
BRPI0616156A2 (pt) 2011-06-07
HRP20100272T2 (hr) 2010-07-31
HK1120506A1 (en) 2009-04-03
US20070167497A1 (en) 2007-07-19
CN101287708B (zh) 2012-02-29
RS51349B (sr) 2011-02-28
CA2621805C (fr) 2011-05-10
NO20081844L (no) 2008-05-29
PL1937639T3 (pl) 2010-07-30
AU2006293605A1 (en) 2007-03-29
MA29791B1 (fr) 2008-09-01
ATE459603T1 (de) 2010-03-15
PT1937639E (pt) 2010-04-23
WO2007034312A2 (fr) 2007-03-29

Similar Documents

Publication Publication Date Title
TNSN08139A1 (fr) Composes therapeutiques
MA31419B1 (fr) Derives de pyridine
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
TNSN07022A1 (fr) Derives de pyridine
MA29926B1 (fr) Derives de pyrazine
TN2011000316A1 (fr) Derives de sulfonamides
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
MA29550B1 (fr) Derives de n- (pyridine-2-yl) - sulfonamide
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA38138A1 (fr) Dérivés inédits de quinolone
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
TN2009000204A1 (fr) Spirocetones servant d'inhibiteurs d'acetyl-coa-carboxylase
MA30487B1 (fr) Nouveaux composes heterocycliques
MA33670B1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
MA31433B1 (fr) Inhibiteurs de la p70 s6 kinase
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
MY148480A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
TN2009000028A1 (fr) Agonistes de ep2
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MY139941A (en) Indole derivatives
MY147677A (en) Piperazinyl derivatives useful in the treatment of gpr38 receptor mediated diseases
MA49127B1 (fr) Dérivés d'indole n-substitués
MA27661A1 (fr) Indolone-oxazolidinones antibacteriennes, intermediaires pour leur preparation et compositions pharmaceutiques les contenant